AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
According to recent research from Kampala, Uganda, "A randomized open-label trial. including 834 pregnant women, examined efficacy and recorded adverse events of ivermectin (ivc) and albendazole (alb) alone and combined (comb) oil soil-transmitted helminth infections(STHs) in the second trimester of pregnancy. One abortion Occurred in the all) group and 10 stillbirths (1, 5 3, and 1) in the ivc, alb. comb, and the reference group (ref) with no STHs, respectively."
"Two babies were born with congenital abnormalities (1 [ivc] and I [ref]). The prevalence of anemia at first antenatal care (ANC) visit was 20.6% (23.7% [ivc]. 21.1% [alb], 22.2%, [comb], and 16.1% [ref]). Anemia was reduced to 8.5% at 36 weeks of gestation with 10.9% (ivc), 11.5% (alb), 7.7%, (comb), and 6.9% (ref). Hookworm cure rates were 29.4% (ivc), 95.5% (alb). and 92.6% (comb)," wrote R. Ndyomugyenyi and colleagues (see also Adverse Drug Reactions).
The researchers concluded: "No Severe adverse events were reported by the women after the administration of ivc, alb, or comb during the second trimester of pregnancy, but long-term pharmacovigillance is needed to assess safety of ivc, alb, or ...
Source: HighBeam Research, Findings from R. Ndyomugyenyi and co-authors provide new insights...